The noninvasive test provides a beneficial screening tool for patients 45 and older at average risk for colorectal cancer.

The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...

The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for ...

The global PD-1/PD-L1 inhibitors market is projected to witness remarkable growth over the next decade, with an estimated ...

Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...

In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) cleared Opdivo (nivolumab) for use with platinum-based chemo to reduce the size ...

Bristol Myers Squibb has received FDA approval for Opdivo (nivolumab) combined with chemotherapy as a perioperative treatment ...

A phase 2/3 non-inferiority study compared de-escalation strategies to standard chemoradiation in patients with human ...

BriaCell Therapeutics announced that its Bria-IMT cell therapy, plus an immune checkpoint inhibitor regimen, achieved ...

Police departments in the Los Angeles area are ramping up patrols around synagogues during Rosh Hashana this week — though authorities say they have not received any ...

Before Hurricane Helene's landfall last week the National Weather Service began an all-out blitz to alert emergency planners, ...